SCHEMBL639976

SCHEMBL639976

CCOC(=O)C(c1ccccc1)n1c(=O)n(C(=O)OCC)c2cc(Cl)ccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.60
L3MBTL1 Q9Y468 4/20 0.60
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 5/20 0.47
TP53 P04637 1/20 0.47
GAA P10253 2/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
GLA P06280 1/20 0.38
PLA2G4A P47712 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641139 0.89 LMNA (0.48) LMNAL3MBTL1SMN1; SMN2ALDH1A1TP53
SCHEMBL641167 0.88 L3MBTL1 (0.48) LMNAL3MBTL1SMN1; SMN2ALDH1A1TP53
SCHEMBL639801 0.82 LMNA (0.42) LMNAL3MBTL1SMN1; SMN2ALDH1A1GAA
SCHEMBL640561 0.81 LMNA (0.42) LMNAL3MBTL1SMN1; SMN2ALDH1A1GAA
SCHEMBL642618 0.78 LMNA (0.41) LMNAL3MBTL1SMN1; SMN2ALDH1A1TP53
SCHEMBL639642 0.77 MEN1 (0.46) LMNAL3MBTL1SMN1; SMN2ALDH1A1GAA
SCHEMBL640579 0.76 MMP8 (0.36) LMNAL3MBTL1SMN1; SMN2ALDH1A1TP53
Ethoxycarbonyl Group SCHEMBL27776863 0.73 MDM2 (0.47) LMNAL3MBTL1ALDH1A1GAACYP1A2
SCHEMBL639977 0.70 LMNA (0.67) LMNAL3MBTL1SMN1; SMN2ALDH1A1TP53
SCHEMBL640324 0.68 MEN1 (0.41) LMNAL3MBTL1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LMNA 886/4885L3MBTL1 3180/4885SMN1; SMN2 3474/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LMNA 886/4885L3MBTL1 3180/4885SMN1; SMN2 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.